Abstracts tagged "denosumab"

Abstract Number: 322 • 2017 ACR/ARHP Annual Meeting
Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Sonia Doddoli, Pierre Lafforgue and Thao Pham, Rheumatology, APHM, Aix Marseille Univ, Marseille, France
Background/Purpose: Safety of denosumab, a fully human monoclonal antibody against RANKL developed for osteoporosis and prevention of fracture remains unclear in kidney transplanted patients. A…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 323 • 2016 ACR/ARHP Annual Meeting
Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study
David W Dempster^1,2, NS Daizadeh³, A Fahrleitner-Pammer⁴, Jens-Erik Beck Jensen⁵, DL Kendler⁶, Ivo Valter⁷, Rachel B Wagman³, Susan Yue³ and Jacques P Brown⁸, ¹Columbia University, New York, NY, ²Helen Hayes Hospital, West Haverstraw, NY, ³Amgen Inc., Thousand Oaks, CA, ⁴Medical University, Graz, Austria, ⁵Hvidovre University Hospital, Hvidovre, Denmark, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Center for Clinical and Basic Research, Tallinn, Estonia, ⁸Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada
Background/Purpose: Denosumab (DMAb) has been associated with low incidence of spine and non-spine, including hip, fractures through 10 years of treatment (Bone ASBMR 2015). Questions…
Abstract Number: 330 • 2016 ACR/ARHP Annual Meeting
Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Marlène Aubailly¹, Bernard Combe², Cécile Gaujoux-Viala³, Cédric Lukas⁴, Jacques Morel⁵ and Hélène Che¹, ¹rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: Denosumab is a RANK ligand antibody and the first biologic agent used for the treatment of post-menopausal osteoporosis (OP) and prevention of bone metastases…
Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
DL Kendler¹, A Chines², ML Brandi³, S Papapoulos⁴, EM Lewiecki⁵, J-Y Reginster⁶, C Roux⁷, M Munoz Torres⁸, A Wang² and HG Bone⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁶University of Liège, Liège, Belgium, ⁷Paris Descartes University, Paris, France, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…
Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
E Siris¹, N Pannacciulli², PD Miller³, EM Lewiecki⁴, R Chapurlat⁵, E Jódar-Gimeno⁶, NS Daizadeh², RB Wagman² and JA Kanis⁷, ¹Columbia University Medical Center, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Hôpital Edouard Herriot, Lyon, France, ⁶Hospital Universitario Quirónsalud Madrid, Madrid, Spain, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
Abstract Number: 358 • 2016 ACR/ARHP Annual Meeting
Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California
Purva Chhibar¹ and Glenn Ehresmann², ¹Internal Medicine, Division of Rheumatology, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA, ²Internal Medicine, Division of Rheumatology, University of Southern Californnia, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: Patients with autoimmune diseases are at increased risk of early onset osteoporosis due to multiple reasons including prolonged exposure to corticosteroids and the disease…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Jacques P Brown¹, S Ferrari², N Gilchrist³, Jens-Erik Beck Jensen⁴, N Pannacciulli⁵, Chris Recknor⁶, Christian Roux⁷, Shawna Smith⁵, Ove Törring⁸, Ivo Valter⁹, Rachel B Wagman⁵, A Wang⁵ and SR Cummings¹⁰, ¹Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³The Princess Margaret Hospital, Christchurch, New Zealand, ⁴Hvidovre University Hospital, Hvidovre, Denmark, ⁵Amgen Inc., Thousand Oaks, CA, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Paris Descartes University, Paris, France, ⁸Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ⁹Center for Clinical and Basic Research, Tallinn, Estonia, ¹⁰SFCC, CPMC Research Institute & UCSF, San Francisco, CA
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…
Abstract Number: 347 • 2015 ACR/ARHP Annual Meeting
Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
NB Watts¹, JP Brown², S Papapoulos³, EM Lewiecki⁴, DL Kendler⁵, P Dakin⁶, RB Wagman⁶, A Wang⁶, NS Daizadeh⁶, S Smith⁶ and HG Bone⁷, ¹Mercy Health, Cincinnati, OH, ²Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Denosumab (DMAb) is approved for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. In the pivotal 3-year FREEDOM trial comparing…
Abstract Number: 353 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
Hisaji Oshima¹, Mari Ushikubo¹, Kumiko Akiya¹, Ikuko Tanaka², Shigenori Tamaki² and Keisuke Izumi³, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Although weekly teriparatide (56.5ug, wTPTD) and denosmab (DMAB) have been developed as potent anti-osteoporotic agents, effects of these agents on prevention of osteoporotic fractures…
Abstract Number: 356 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Keisuke Hagihara⁴, Hideki Yoshikawa⁵ and Takaaki Noguchi⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Kampo Medicine, Osaka University, Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ⁶Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan
Background/Purpose: In patients with rheumatic diseases (RD), pro-inflammatory cytokines induce receptor activator of nuclear factor kappa-B ligand (RANKL), which plays a crucial role in inducing…
Abstract Number: 365 • 2015 ACR/ARHP Annual Meeting
Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
JP Brown¹, P Dakin², P Hadji³, MR McClung⁴, PD Miller⁵, J-Y Reginster⁶, RB Wagman², A Wang² and E McCloskey⁷, ¹Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Philipps-University of Marburg, Marburg, Germany, ⁴Oregon Osteoporosis Center, Portland, OR, ⁵Colorado Center for Bone Research, Lakewood, CO, ⁶University of Liège, Liège, Belgium, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Bone turnover markers (BTMs) respond faster than bone mineral density as an indicator of response to therapy in osteoporotic patients; however, it remains unclear…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 918 • 2014 ACR/ARHP Annual Meeting
Findings from Denosumab (Prolia^®) Postmarketing Safety Surveillance for Serious Infections
W Golden¹, DB Crittenden¹, M Uhart¹, RB Wagman¹, C Stehman-Breen¹, S Papapoulos² and NB Watts³, ¹Amgen Inc., Thousand Oaks, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH
Background/Purpose: Prolia has marketing authorization in the EU, US, Canada, Japan, and over 40 countries or administrative districts worldwide for the treatment of postmenopausal women…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].